The therapeutic potential of targeting SYK was demonstrated in a recent study showing that the SYK inhibitor fostamatinib mitigated myeloid proinflammatory responses believed to contribute to the immunopathogenesis of severe COVID-19 [78]. This evidence concerns the gene SYK and COVID-19.